Trevi Therapeutics Inc (NASDAQ: TRVI) is 110.45% higher on its value in year-to-date trading and has touched a low of $0.97 and a high of $4.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TRVI stock was last observed hovering at around $2.88 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $2.82, the stock is -3.28% and -7.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.17 million and changing -2.08% at the moment leaves the stock -3.65% off its SMA200. TRVI registered 164.79% gain for a year compared to 6-month gain of 8.88%. The firm has a 50-day simple moving average (SMA 50) of $3.0767 and a 200-day simple moving average (SMA200) of $2.921875.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.44% loss in the last 1 month and extending the period to 3 months gives it a -3.09%, and is 1.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.52% over the week and 6.94% over the month.
Trevi Therapeutics Inc (TRVI) has around 25 employees, a market worth around $216.76M and $0.00M in sales. Distance from 52-week low is 190.72% and -29.50% from its 52-week high. The company has generated returns on investments over the last 12 months (-74.13%).
Trevi Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.12.The EPS is expected to shrink by -67.14% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
121.0 institutions hold shares in Trevi Therapeutics Inc (TRVI), with institutional investors hold 81.57% of the company’s shares. The shares outstanding are 68.28M, and float is at 43.76M with Short Float at 4.01%. Institutions hold 80.61% of the Float.
The top institutional shareholder in the company is NEA MANAGEMENT COMPANY, LLC with over 11.37 million shares valued at $33.88 million. The investor’s holdings represent 11.4255 of the TRVI Shares outstanding. As of 2024-06-30, the second largest holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with 7.38 million shares valued at $22.0 million to account for 7.4169 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 5.03 million shares representing 5.0513 and valued at over $14.98 million, while VIKING GLOBAL INVESTORS LP holds 4.4213 of the shares totaling 4.4 million with a market value of $13.11 million.
Trevi Therapeutics Inc (TRVI) Insider Activity
The most recent transaction is an insider sale by GOOD JENNIFER L, the company’s President & CEO. SEC filings show that GOOD JENNIFER L sold 4,219 shares of the company’s common stock on Sep 06 ’24 at a price of $3.03 per share for a total of $12784.0. Following the sale, the insider now owns 0.21 million shares.
Trevi Therapeutics Inc disclosed in a document filed with the SEC on Sep 09 ’24 that GOOD JENNIFER L (President & CEO) sold a total of 1,840 shares of the company’s common stock. The trade occurred on Sep 09 ’24 and was made at $3.04 per share for $5587.0. Following the transaction, the insider now directly holds 0.21 million shares of the TRVI stock.
Still, SEC filings show that on Sep 05 ’24, GOOD JENNIFER L (President & CEO) disposed off 40,277 shares at an average price of $3.11 for $0.13 million. The insider now directly holds 213,313 shares of Trevi Therapeutics Inc (TRVI).
